Dyne Therapeutics (DYN) announced that the Ministry of Health, Labour and Welfare in Japan has granted Orphan Drug designation for zeleciment basivarsen or z-basivarsen, for the treatment of myotonic muscular dystrophy type 1. Z-basivarsen is currently being evaluated in the Phase 1/2 ACHIEVE clinical trial.
Z-basivarsen has also been granted Breakthrough Therapy, Fast Track and Orphan Drug designations from the FDA, and Orphan Drug designation from the European Medicines Agency for the treatment of individuals with muscular dystrophy type 1.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.